KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Tax Provisions (2016 - 2025)

Regeneron Pharmaceuticals has reported Tax Provisions over the past 15 years, most recently at $199.1 million for Q4 2025.

  • Quarterly results put Tax Provisions at $199.1 million for Q4 2025, up 392.82% from a year ago — trailing twelve months through Dec 2025 was $725.8 million (up 97.6% YoY), and the annual figure for FY2025 was $725.8 million, up 97.6%.
  • Tax Provisions for Q4 2025 was $199.1 million at Regeneron Pharmaceuticals, down from $303.3 million in the prior quarter.
  • Over the last five years, Tax Provisions for REGN hit a ceiling of $653.9 million in Q2 2021 and a floor of -$21.3 million in Q1 2024.
  • Median Tax Provisions over the past 5 years was $127.4 million (2022), compared with a mean of $155.5 million.
  • Biggest five-year swings in Tax Provisions: surged 2927.31% in 2021 and later plummeted 152.99% in 2024.
  • Regeneron Pharmaceuticals' Tax Provisions stood at $274.4 million in 2021, then tumbled by 53.5% to $127.6 million in 2022, then tumbled by 109.4% to -$12.0 million in 2023, then surged by 436.67% to $40.4 million in 2024, then skyrocketed by 392.82% to $199.1 million in 2025.
  • The last three reported values for Tax Provisions were $199.1 million (Q4 2025), $303.3 million (Q3 2025), and $127.1 million (Q2 2025) per Business Quant data.